PIONERA will evaluate the efficacy and safety of giredestrant (oral SERD) compared with fulvestrant, both combined with the investigator’s choice of CDK4/6i in participants with ER+ and HER2− aBC who have developed resistance to adjuvant ET. Here, CDK4 is linked to aneurysmal bone cyst.